[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201991540A1 - PHARMACEUTICAL MEDICINAL FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF RESPIRATORY DISORDERS - Google Patents

PHARMACEUTICAL MEDICINAL FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF RESPIRATORY DISORDERS

Info

Publication number
EA201991540A1
EA201991540A1 EA201991540A EA201991540A EA201991540A1 EA 201991540 A1 EA201991540 A1 EA 201991540A1 EA 201991540 A EA201991540 A EA 201991540A EA 201991540 A EA201991540 A EA 201991540A EA 201991540 A1 EA201991540 A1 EA 201991540A1
Authority
EA
Eurasian Patent Office
Prior art keywords
task
respiratory disorders
treatment
forms containing
application
Prior art date
Application number
EA201991540A
Other languages
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/082542 external-priority patent/WO2018114501A1/en
Publication of EA201991540A1 publication Critical patent/EA201991540A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение касается новых фармацевтических лекарственных форм, содержащих сильные и селективные ингибиторы каналов TASK-1 и/или TASK-3, и их применения для лечения и/или профилактики нарушений дыхания, включая нарушения дыхания во сне, такие как обструктивное и центральное апноэ сна и храп.The present invention relates to new pharmaceutical dosage forms containing potent and selective inhibitors of the TASK-1 and / or TASK-3 channels, and their use for the treatment and / or prevention of respiratory disorders, including respiratory disorders in sleep, such as obstructive and central sleep apnea and snore.

EA201991540A 2017-02-24 2017-12-13 PHARMACEUTICAL MEDICINAL FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF RESPIRATORY DISORDERS EA201991540A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17157805 2017-02-24
PCT/EP2017/082542 WO2018114501A1 (en) 2016-12-21 2017-12-13 Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy

Publications (1)

Publication Number Publication Date
EA201991540A1 true EA201991540A1 (en) 2019-11-29

Family

ID=58185328

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991540A EA201991540A1 (en) 2017-02-24 2017-12-13 PHARMACEUTICAL MEDICINAL FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF RESPIRATORY DISORDERS

Country Status (1)

Country Link
EA (1) EA201991540A1 (en)

Similar Documents

Publication Publication Date Title
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
PH12018501235A1 (en) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
BR112015018168A2 (en) soft rock inhibitors
PH12017501421A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
BR112015018284A2 (en) amides as sodium channel modulators
EA201590933A1 (en) NEW ORAL BIO-ACCESSIBLE CONNECTIONS, MODULATING RESPIRATION CONTROL, AND METHODS OF THEIR USE
CO2022005783A2 (en) a₂c adrenergic receptor inhibitors
EA202191480A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1- AND TASK-3-CHANNEL INHIBITORS AND THEIR APPLICATION FOR THERAPY OF RESPIRATORY DISORDERS
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
EA201991540A1 (en) PHARMACEUTICAL MEDICINAL FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF RESPIRATORY DISORDERS
EA201991817A1 (en) Intranasal Composition Including Betagistin
EA201991538A1 (en) PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS AND THEIR APPLICATION FOR TREATMENT OF RESPIRATORY DISORDERS
AR110417A1 (en) FORMS OF PHARMACEUTICAL ADMINISTRATION CONTAINING INHIBITORS OF TASK-1 AND TASK-3 CHANNELS AND THEIR USE FOR THE TREATMENT OF RESPIRATORY DISORDERS
EA201990341A1 (en) SUBSTITUTED DIAZAHETEROBICYCLIC COMPOUNDS AND THEIR APPLICATION
BR112017003425A2 (en) pharmaceutical composition for the treatment of acute dental or mandibular pain